REVISE : re-evaluating the inhibition of stress erosions in the ICU-statistical analysis plan for a randomized trial
© 2023. The Author(s)..
BACKGROUND: The REVISE (Re-Evaluating the Inhibition of Stress Erosions in the ICU) trial will evaluate the impact of the proton pump inhibitor pantoprazole compared to placebo in invasively ventilated critically ill patients.
OBJECTIVE: To outline the statistical analysis plan for the REVISE trial.
METHODS: REVISE is a randomized clinical trial ongoing in intensive care units (ICUs) internationally. Patients ≥ 18 years old, receiving invasive mechanical ventilation, and expected to remain ventilated beyond the calendar day after randomization are allocated to either 40 mg pantoprazole intravenously or placebo while mechanically ventilated.
RESULTS: The primary efficacy outcome is clinically important upper GI bleeding; the primary safety outcome is 90-day mortality. Secondary outcomes are ventilator-associated pneumonia, Clostridioides difficile infection, new renal replacement therapy, ICU and hospital mortality, and patient-important GI bleeding. Tertiary outcomes are total red blood cells transfused, peak serum creatinine concentration, and duration of mechanical ventilation, ICU, and hospital length of stay. Following an interim analysis of results from 2400 patients (50% of 4800 target sample size), the data monitoring committee recommended continuing enrolment.
CONCLUSIONS: This statistical analysis plan outlines the statistical analyses of all outcomes, sensitivity analyses, and subgroup analyses. REVISE will inform clinical practice and guidelines worldwide.
TRIAL REGISTRATION: www.
CLINICALTRIALS: gov NCT03374800. November 21, 2017.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Trials - 24(2023), 1 vom: 06. Dez., Seite 796 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Heels-Ansdell, Diane [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.12.2023 Date Revised 15.12.2023 published: Electronic ClinicalTrials.gov: NCT03374800 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13063-023-07794-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365487805 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365487805 | ||
| 003 | DE-627 | ||
| 005 | 20231227132705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-023-07794-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1229.xml |
| 035 | |a (DE-627)NLM365487805 | ||
| 035 | |a (NLM)38057875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Heels-Ansdell, Diane |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a REVISE |b re-evaluating the inhibition of stress erosions in the ICU-statistical analysis plan for a randomized trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2023 | ||
| 500 | |a Date Revised 15.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03374800 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: The REVISE (Re-Evaluating the Inhibition of Stress Erosions in the ICU) trial will evaluate the impact of the proton pump inhibitor pantoprazole compared to placebo in invasively ventilated critically ill patients | ||
| 520 | |a OBJECTIVE: To outline the statistical analysis plan for the REVISE trial | ||
| 520 | |a METHODS: REVISE is a randomized clinical trial ongoing in intensive care units (ICUs) internationally. Patients ≥ 18 years old, receiving invasive mechanical ventilation, and expected to remain ventilated beyond the calendar day after randomization are allocated to either 40 mg pantoprazole intravenously or placebo while mechanically ventilated | ||
| 520 | |a RESULTS: The primary efficacy outcome is clinically important upper GI bleeding; the primary safety outcome is 90-day mortality. Secondary outcomes are ventilator-associated pneumonia, Clostridioides difficile infection, new renal replacement therapy, ICU and hospital mortality, and patient-important GI bleeding. Tertiary outcomes are total red blood cells transfused, peak serum creatinine concentration, and duration of mechanical ventilation, ICU, and hospital length of stay. Following an interim analysis of results from 2400 patients (50% of 4800 target sample size), the data monitoring committee recommended continuing enrolment | ||
| 520 | |a CONCLUSIONS: This statistical analysis plan outlines the statistical analyses of all outcomes, sensitivity analyses, and subgroup analyses. REVISE will inform clinical practice and guidelines worldwide | ||
| 520 | |a TRIAL REGISTRATION: www | ||
| 520 | |a CLINICALTRIALS: gov NCT03374800. November 21, 2017 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clostridioides difficile infection | |
| 650 | 4 | |a Critically ill | |
| 650 | 4 | |a Gastrointestinal bleeding | |
| 650 | 4 | |a Stress ulceration | |
| 650 | 4 | |a Ventilator-associated pneumonia | |
| 650 | 7 | |a Pantoprazole |2 NLM | |
| 650 | 7 | |a D8TST4O562 |2 NLM | |
| 650 | 7 | |a Proton Pump Inhibitors |2 NLM | |
| 700 | 1 | |a Billot, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Thabane, Lehana |e verfasserin |4 aut | |
| 700 | 1 | |a Alhazzani, Waleed |e verfasserin |4 aut | |
| 700 | 1 | |a Deane, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Guyatt, Gordon |e verfasserin |4 aut | |
| 700 | 1 | |a Finfer, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Lauzier, François |e verfasserin |4 aut | |
| 700 | 1 | |a Myburgh, John |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Arabi, Yaseen |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, John |e verfasserin |4 aut | |
| 700 | 1 | |a English, Shane |e verfasserin |4 aut | |
| 700 | 1 | |a Muscedere, John |e verfasserin |4 aut | |
| 700 | 1 | |a Ostermann, Marlies |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatesh, Bala |e verfasserin |4 aut | |
| 700 | 1 | |a Zytaruk, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Hardie, Miranda |e verfasserin |4 aut | |
| 700 | 1 | |a Hammond, Naomi |e verfasserin |4 aut | |
| 700 | 1 | |a Knowles, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Saunders, Lois |e verfasserin |4 aut | |
| 700 | 1 | |a Poole, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Fares, Abdulrahman |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Deborah |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trials |d 2006 |g 24(2023), 1 vom: 06. Dez., Seite 796 |w (DE-627)NLM161320430 |x 1745-6215 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:1 |g day:06 |g month:12 |g pages:796 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13063-023-07794-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 1 |b 06 |c 12 |h 796 | ||